Assays for the analysis of P-glycoprotein in acute myeloid leukemia and CD34 subsets of AML blasts

Leukemia

Volumn 11, Issue 7, 1997, Pages 1160-1165

  Sonneveld, P ^a   Wiemer, E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; Cyclosporin; MDR; Resistance; SDZ PSC 833

Indexed keywords

ANTIBODY; CD34 ANTIGEN; CD56 ANTIGEN; GLYCOPROTEIN P; RHODAMINE; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; ASSAY; BLAST CELL; CELL SELECTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE SUBPOPULATION; MULTIDRUG RESISTANCE; ONCOGENE C KIT; PRIORITY JOURNAL;

EID: 0030790531     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400680     Document Type: Article

References (11)

1. Yates W, Glidewell O, Wiernik PH, Cooper MR, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchison JL, Raich P, Nissen N, Ellison RR, Felick R, James GW, Falkson G, Silver RT, Hauani F, Green NM, Henderson E, Lone L, Holland JF. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982; 60: 454-462.
2. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, McGlare PB, Edelstein M, Harrington DP, O'Connell MJ. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79: 1924-1930.
3. Mayer JR, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E. Intensive postremission chemotherapy in adults with acute myeloid leukemia. New Engl J Med 1994; 331: 896-903.
4. Rees JKH, Gray RG, Swirsky D, Hayhoe FGJ. Principal results of the Medical Research Council's 8th Acute Myeloid Leukemia trial. Lancet 1986; 2: 1236-1241.
5. Buchner T, Urbanitz D, Hiddeman W, Ruhl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kuse R, Zeile G. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985; 3: 1583-1589.
6. Vogler WR, Winton EF, Gordon DS, Raney MR, Go B, Mayer L. A randomized comparison of postremission therapy in acute myelogenous leukemia: a South-Eastern Cancer Study Group trial. Blood 1984; 63: 1039-1045.
7. Zittoun RA, Mandelli F, Willemze R, Witte TD, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Strickmans P, Rotoli B, Leoni P, Peetermans M, Dardenne M, Vegna M, Petti M, Solbu G, Suciu S. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New Eng J Med 1995; 332: 217-223.
8. Löwenberg B, Van Putten WLJ, Verdonck LF, Dekker AW, De Gast CG, Willemze R, Zwaan FE, De Planque H, Abels J, Sonneveld P, Van der Lelie J, Goudsmit R, Sizoo W, Hagenbeek A. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. J Clin Oncol 1990; 8:287-294.
9. Bishop JF, Matthews JP, Young GA. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710-1717.
10. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. New Engl J Med 1995; 332: 1678-1683.
11. Löwenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, Cauchie C, Peetermans M, Solbu G, Suciu S. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the EORTC Leukemia Group. J Clin Oncol 1989; 7: 1268-1274.